Demeclocycline chemical structure
Find information on thousands of medical conditions and prescription drugs.

Demeclocycline

Demeclocycline (marketed as Declomycin®, Declostatin® and Ledermycin®) is a member of the tetracycline antibiotics group used in various types of bacterial infections. One of its other registered uses is the treatment of hyponatremia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective. It is derived from the Streptomyces aureofaciens fungal strain. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Mode of action

Its use as an antibiotic is particularly in Lyme disease, acne and bronchitis. Resistance is gradually becoming more common. As with related tetracycline antibiotics, demeclocycline acts by binding to the 30S- and 50S-RNA, which impairs protein synthesis by bacteria. It is therefore bacteriostatic (it impairs bacterial growth but does not kill bacteria directly). Demeclocycline is rarely used for infections.

The use in SIADH actually relies on a side-effect of tetracycline antibiotics; many may cause diabetes insipidus (dehydration due to the inability to concentrate urine). It is not completely understood why demeclocycline impairs the action of antidiuretic hormone, but it is thought that it blocks the binding of the hormone to its receptor.

Side-effects and interactions

These are similar to other tetracyclines. Hypersensitivity may occur. Skin reactions with sunlight have been reported.

Contraindications

As other tetracyclines, demeclocycline is contraindicated in children and pregnant or nursing women. All members of this class interfere with bone development and may discolour teeth.

Read more at Wikipedia.org


[List your site here Free!]


Donor-Acquired Small Cell Lung Cancer Following Pulmonary Transplantation - )
From CHEST, 9/1/01 by Anthony G. De Soyza

We describe a case of donor-acquired small cell lung cancer after pulmonary transplantation for cystic fibrosis. The recipient was an ex-smoker with minimal smoking history and had been abstinent for 20 years. At the time of death, the donor chest radiographic finding was normal. The recipient had multiple posttransplant bronchoscopies and a normal CT scan result at 4 months after transplantation. The recipient presented 13 months after transplantation with metastatic disease. He did not respond to chemotherapy and died shortly thereafter. Molecular genetic techniques revealed that the primary tumor and metastases were different to recipient tissues, confirming the donor origin. (CHEST 2001; 120:1030-1031)

Key words: bronchial neoplasm; lung transplantation; postoperative complications

We describe a case of donor-acquired small cell lung cancer after pulmonary transplantation for cystic fibrosis. Donor-acquired small cell lung carcinoma has never been described as a consequence of pulmonary transplantation, reflecting the carrel examination and selection of potential donor tissue, prior to grafting, by transplant surgeons.

CASE REPORT

A 25-year old man underwent bilateral lung transplantation for end-stage cystic fibrosis. His donor was a 50-year-old man, an ex-smoker with a 10-pack-year history who had abstained for 20 years prior to suffering a catastrophic subarachnoid hemorrhage. The recipient's posttransplant progress was straightforward, although a Pseudomonas empyema required drainage and IV antibiotics. Immunosuppression was conventional, with cyclosporine, azathioprine, and steroids following a 3-day course of induction antithymocyte globulin, as is routine at our center. Results of a CT scan of his chest performed at 4 months in order to investigate retrosternal pain were unremarkable. Surveillance bronchoscopy and transbronchial biopsy were carried out at 1 week, 3 months, 6 months, and 9 months. There was never any evidence of rejection on these biopsies (International Society for Heart-Lung Transplantation grade A1 or less), and no other endobronchial or histologic abnormalities were seen.

The patient presented 13 months after transplant with severe back pain after no obvious injury. Physical examination revealed local tenderness over the lumbosacral spine and right sacroiliac joint but no evidence of lymphadenopathy. Neurologic examination findings of the lower limbs were normal, as was sphincter control.

Investigations

Routine biochemistry revealed hyponatremia of 130 mmol/L with a grossly elevated alkaline phosphatase (1,212 IU/L; normal range, 35 to 115 IU/L). Bilirubin and alaninine transaminase levels were normal. Total and ionized calcium levels were raised. Results of thyroid function tests and prostate specific antigen were normal. C-reactive protein was elevated at 304 mg/L (normal range, 0 to 4 mg/L). Serum immunoelectrophoresis detected no paraproteins, and no Bence-Jones proteins were detected in the urine. The whole-blood cyclosporine level on hospital admission was 232 ng/mL.

Plain radiography confirmed a sclerotic lesion of the right scapula and also of the right sacral alae. Radioisotope bone scanning revealed numerous "hot spots" consistent with metastatic disease. CT of the abdomen revealed intrahepatic masses, and a CT-guided liver biopsy was performed. Histology revealed metastatic small cell carcinoma.

Progress

The patient was fully informed of his diagnosis. His cyclosporine dose was reduced to attain a level of 100 to 150 ng/mL. Demeclocycline was used to control hyponatremia. Rescue analgesia was commenced IV with ketamine and morphine and converted to oral when satisfactory analgesia was obtained. A modified regimen of carboplatin and oral etoposide was given as previously described.[1] Carboplatin was given as a single dose, 192 mg (adjusted to glomerular filtration rate), with a 3-day course of oral etoposide, 50 mg bid. Local radiotherapy was administered to the lumbar spine after the development of signs consistent with progressive disease. Pamidronate, 60 mg, was administered IV for metastatic bone pain.

There was no clinical response to chemotherapy, and the patient died 1 month after hospital admission. Consent was obtained for a postmortem examination; there were multiple liver and bone metastases together with a single small nodule in the allografted right lung. The esophagus was macroscopically normal.

Genetic Analysis

It was not possible to discern if the tumor was of donor or recipient origin using conventional techniques, as both the donor and recipient were men. Genetic analysis of the postmortem specimens of normal lung tissue, the lung primary, normal liver, and affected liver tissue was therefore carried out. Molecular genetic analysis was carried out on extracted DNA from donor lung tissue and recipient liver and heart using two randomly selected molecular probes, F13A01 and TH01. We used these probes to test if there were different allelic patterns between the tumor/metastases and nonaffected recipient tissue. If the patterns were different, then this would confirm the tumor was of donor origin. Affected liver was defined as liver tissue that appeared to have frank metastasis, while nonaffected had no evidence of macroscopic metastatic disease. Distinct and differing alleles were seen between affected liver/primary lung tumor and nonaffected heart/liver. The allelic pattern confirmed that the affected liver and primary lung tumor were syngeneic and distinct from the recipient heart and nonaffected liver, thus confirming that the tumor was of donor origin (Fig 1). A mixed allelic pattern of both donor and recipient appeared in the nonaffected lung, which we propose was secondary to a genetic admixture of recipient monocyte-derived alveolar macrophages and donor pneumocytes.

[ILLUSTRATION OMITTED]

DISCUSSION

Donor-acquired small cell lung carcinoma has never been described as a consequence of pulmonary transplantation, reflecting the careful examination and selection of potential donor tissue, prior to grafting, by transplant surgeons. Findings of the donor chest radiograph did not suggest any pulmonary pathology, and results of a CT scan, performed for other reasons, at 4 months, were normal even in retrospect. The patient underwent regular chest radiography in the course of his follow-up, but the nodule in the right lung was only discovered with the CT scan that characterized his metastatic disease. Regular bronchoscopies failed to demonstrate the primary lesion. The progression of the tumor in this patient was rapid given the previous normal CT scan, and was at the extremes of that seen in patients with native small cell cancer. It is tempting to speculate the role of immunosuppressants in this, given their effect on tumor surveillance.

We have made efforts to contact transplant centers that used other donor organs and are unaware of any of complications arising in these recipients. This report raises an important issue: a chronic shortage of donors has resulted in a waiting-list mortality of approximately 50%. A case report has previously questioned the validity of using donors with documented primary intracranial neoplasms as potential donors. Failure to use these patients as donors would reduce donor numbers further.[2] There is now an increasing pressure on transplant centers and their waiting lists due to increasing numbers of both referrals and accepted indications for transplantation. It is therefore unlikely that potential donors with such minimal smoking history would be excluded despite our experience.

REFERENCES

[1] Skarlos DV, Samantas E, Kosmidis P, et al. Randomised comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 1994; 5:601-607

[2] Frank S, Muller J, Bonk C, et al. Transplantation of glioblastoma multiforme through liver transplantation [letter]. Lancet 1998; 352:31

(*) From the Departments of Cardiopulmonary Transplantation (Drs. De Soyza, Dark, and Corris) and Pathology (Dr. Parums), Freeman Hospital, and Department of Molecular Genetics (Dr. Curtis), University of Newcastle upon Tyne, Newcastle upon Tyne, UK.

Manuscript received November 21, 2000; revision accepted February 23, 2001.

Correspondence to: Anthony G. De Soyza, MRCP, Department of Respiratory Medicine, Freeman Hospital, Newcastle upon Tyne, UK; e-mail: Anthony.De-Soyza@ncl.ac.uk

COPYRIGHT 2001 American College of Chest Physicians
COPYRIGHT 2001 Gale Group

Return to Demeclocycline
Home Contact Resources Exchange Links ebay